| adagloxad simolenin (OBI 822) / OBI Pharma |
2018-001438-16: Phase 3 Study of Adagloxad Simolenin (OBI-822)/OBI-821 Treatment for Breast Cancer Patients |
|
|
| Not yet recruiting | 3 | 668 | Europe | Adagloxad simolenin, OBI-821, Capecitabine, OBI-822, OBI-821, N/A, Powder for injection, Film-coated tablet | OBI Pharma, Inc., OBI Pharma, Inc. | Triple Negative Breast Cancer, Breast cancer, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 3 | 668 | Europe, US, RoW | adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment | OBI Pharma, Inc, OBI Pharma, Inc. | Triple Negative Breast Cancer | 12/25 | 12/27 | | |
| OBI-833 / OBI Pharma |
NCT05376423: To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence |
|
|
| Recruiting | 2 | 60 | RoW | OBI-833/OBI-821 | National Taiwan University Hospital | Esophageal Cancer | 12/24 | 06/25 | | |
NCT05442060: To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 60 | RoW | 30 μg OBI-833/100 μg OBI-821, Erlotinib (150 mg daily) | OBI Pharma, Inc | Non-small Cell Lung Cancer | 12/24 | 05/26 | | |
NCT06490198: Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin |
|
|
| Not yet recruiting | 1 | 30 | RoW | OBI-833/OBI-821, Globo H-CRM197 | Chang Gung Memorial Hospital | Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy | 07/26 | 07/27 | | |
| OBI-3424 / OBI Pharma |
S1905, NCT04315324: Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) |
|
|
| Recruiting | 2 | 39 | US | AKR1C3-activated Prodrug OBI-3424, AKR1C3-activated Prodrug TH-3424, Aldo-keto Reductase 1c3-activated Prodrug OBI-3424, OBI 3424, OBI-3424, OBI3424, TH 3424, TH-3424, TH3424 | SWOG Cancer Research Network, National Cancer Institute (NCI) | Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia | 08/28 | 08/32 | | |
| Recruiting | 1/2 | 51 | RoW | AST-3424 | Ascentawits Pharmaceuticals, Ltd | Advanced Solid Tumors, Hepatocellular Carcinoma | 11/25 | 11/25 | | |
NCT03592264: A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 68 | US | OBI-3424 | OBI Pharma, Inc | Solid Tumor, Pancreatic Adenocarcinoma | 02/24 | 03/24 | | |
| OBI-999 / OBI Pharma |
NCT04084366: Phase 1/2 Study of OBI-999 in Patients with Advanced Solid Tumors |
|
|
| Terminated | 1/2 | 44 | US | OBI-999 | OBI Pharma, Inc | Locally Advanced Solid Tumor | 10/23 | 10/23 | | |
| OBI-866 / OBI Pharma |
| No trials found |
| OBI-998 / OBI Pharma |
| No trials found |
| BSI-04702 / OBI Pharma |
| No trials found |
